Journal article
Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis
Abstract
BACKGROUND: Atopic dermatitis is a prevalent condition in children and can be effectively managed with medications such as topical calcineurin inhibitors (pimecrolimus or tacrolimus). A key unresolved safety concern is whether use of topical calcineurin inhibitors is associated with cancer. We systematically reviewed the risk of cancer in patients with atopic dermatitis exposed to topical calcineurin inhibitors.
METHODS: As part of the 2022 …
Authors
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M
Journal
The Lancet Child & Adolescent Health, Vol. 7, No. 1, pp. 13–25
Publisher
Elsevier
Publication Date
January 2023
DOI
10.1016/s2352-4642(22)00283-8
ISSN
2352-4642